Cargando…

Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

BACKGROUND: Treatment with the alpha-glucosidase inhibitor (AGI) acarbose is associated with a significant reduction the risk of cardiovascular events. However, the underlying mechanisms of this effect are unclear. AGIs were recently suggested to participate in stimulating glucagon-like peptide 1 (G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Miao-yan, Yang, Ju-hong, Shan, Chun-yan, Zhou, Hong-tao, Xu, Yan-guang, Wang, Ying, Ren, Hui-zhu, Chang, Bao-cheng, Chen, Li-ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653752/ https://www.ncbi.nlm.nih.gov/pubmed/23642288 http://dx.doi.org/10.1186/1475-2840-12-73

Ejemplares similares

Single-dose acarbose decreased glucose-dependent insulinotropic peptide and glucagon levels in Chinese patients with newly diagnosed type 2 diabetes mellitus after a mixed meal
por: Chen, Zhong, et al.
Publicado: (2016)

Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study
por: Mo, Dan, et al.
Publicado: (2019)

MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
por: Wang, Na, et al.
Publicado: (2018)

MARCH2: Comparative Assessment of Therapeutic Effects of Acarbose and Metformin in Newly Diagnosed Type 2 Diabetes Patients
por: Wang, Guang, et al.
Publicado: (2014)

Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China
por: Zhang, Rong, et al.
Publicado: (2022)

Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial
por: Pan, Qingrong, et al.
Publicado: (2016)

Extension of the Life Span by Acarbose: Is It Mediated by the Gut Microbiota?
por: Wu, Baiyun, et al.
Publicado: (2022)

Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria
por: Pan, Qingrong, et al.
Publicado: (2018)

The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus()
por: Wang, Hua, et al.
Publicado: (2013)

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
por: Lambadiari, Vaia, et al.
Publicado: (2018)

Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance
por: Yun, Peng, et al.
Publicado: (2016)

Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes
por: Song, Lulu, et al.
Publicado: (2021)

Evaluation of the Bioequivalence of Acarbose in Healthy Chinese People
por: Chen, Yan, et al.
Publicado: (2021)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus
por: Riederer, A., et al.
Publicado: (2016)

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
por: Kato, Toru, et al.
Publicado: (2010)

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose
por: Huang, Jie, et al.
Publicado: (2020)

Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release
por: Krämer, Anna L., et al.
Publicado: (2020)

Acarbose is again on the stage
por: Altay, Mustafa
Publicado: (2022)

The bidirectional association of C-peptide with cardiovascular risk in nondiabetic adults and patients with newly diagnosed type 2 diabetes mellitus: a retrospective cohort study
por: Yan, Shuang-Tong, et al.
Publicado: (2022)

Postprandial glucagon-like peptide 1 secretion is associated with urinary albumin excretion in newly diagnosed type 2 diabetes patients
por: Song, Lu-Lu, et al.
Publicado: (2023)

Risk of Dementia After Smoking Cessation in Patients With Newly Diagnosed Atrial Fibrillation
por: Lee, Hui-Jin, et al.
Publicado: (2022)

Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis
por: Costa, Rafaella R., et al.
Publicado: (2021)

Prevalence and clinical characteristics of carotid atherosclerosis in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study
por: Li, Lian-Xi, et al.
Publicado: (2013)

The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
por: Lai, Rose, et al.
Publicado: (2010)

Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis
por: Orman, Eric S., et al.
Publicado: (2019)

Health Care Resource Utilization in Management of Opioid-Naive Patients With Newly Diagnosed Neck Pain
por: Jin, Michael C., et al.
Publicado: (2022)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures
por: Lundgren, Julie R., et al.
Publicado: (2019)

Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus
por: Wang, Xiao-Li, et al.
Publicado: (2016)

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial
por: Griguer, Corinne E, et al.
Publicado: (2021)

Method for evaluating the human bioequivalence of acarbose based on pharmacodynamic parameters
por: Xu, Su-Mei, et al.
Publicado: (2020)

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
por: Eberly, Lauren A., et al.
Publicado: (2021)

On the potential of acarbose to reduce cardiovascular disease
por: Standl, Eberhard, et al.
Publicado: (2014)

Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study
por: Song, Lu-Lu, et al.
Publicado: (2020)

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation
por: Fox, Keith A. A., et al.
Publicado: (2020)

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
por: Seystahl, Katharina, et al.
Publicado: (2022)

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial
por: Gallia, Gary L, et al.
Publicado: (2020)

Centile charts of cervical length in singleton and twin pregnancies between 16 and 24 weeks of gestation
por: Akar, Bertan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8uph9bpj4trlkpo6m0ak3jjpa9